Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Y-Mabs Therapeutics Inc (NASDAQ: YMAB) closed at $13.73 down -1.93% from its previous closing price of $14.00. In other words, the price has decreased by -$1.93 from its previous closing price. On the day, 1.11 million shares were traded. YMAB stock price reached its highest trading level at $14.325 during the session, while it also had its lowest trading level at $13.66.
Ratios:
For a deeper understanding of Y-Mabs Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.72 and its Current Ratio is at 2.92. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on August 16, 2024, initiated with a Overweight rating and assigned the stock a target price of $20.
On June 28, 2024, Truist started tracking the stock assigning a Buy rating and target price of $21.
Wedbush Upgraded its Neutral to Outperform on May 10, 2023, whereas the target price for the stock was revised from $5 to $13.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 13 ’24 when Gad Thomas sold 65,000 shares for $13.47 per share. The transaction valued at 875,550 led to the insider holds 97,681 shares of the business.
Gad Thomas sold 30,000 shares of YMAB for $389,100 on Sep 16 ’24. The CHIEF BUSINESS OFFICER now owns 67,681 shares after completing the transaction at $12.97 per share. On Sep 13 ’24, another insider, Thomas Gad, who serves as the Officer of the company, bought 100,000 shares for $13.74 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, YMAB now has a Market Capitalization of 611943360 and an Enterprise Value of 535411808. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.07 while its Price-to-Book (P/B) ratio in mrq is 6.42. Its current Enterprise Value per Revenue stands at 6.186 whereas that against EBITDA is -19.827.
Stock Price History:
Over the past 52 weeks, YMAB has reached a high of $20.90, while it has fallen to a 52-week low of $4.69. The 50-Day Moving Average of the stock is 7.33%, while the 200-Day Moving Average is calculated to be 8.97%.
Shares Statistics:
For the past three months, YMAB has traded an average of 281.32K shares per day and 341540 over the past ten days. A total of 43.67M shares are outstanding, with a floating share count of 37.02M. Insiders hold about 16.94% of the company’s shares, while institutions hold 57.36% stake in the company. Shares short for YMAB as of 1724976000 were 4190440 with a Short Ratio of 14.90, compared to 1722384000 on 4659507. Therefore, it implies a Short% of Shares Outstanding of 4190440 and a Short% of Float of 11.29.
